13/03/2024 – AB Science today announced the publication of new preclinical results for masitinib in neurodegenerative diseases Download PDF Post navigationPreviousPrevious post:Summary of the live webcast held on March 4, 2024, providing an update on AB Science developmentNextNext post:AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSRelated PostsA new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientsMay 7, 2024The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceMay 2, 2024AB Science announces a slight delay in the publication of its 2023 annual financial reportApril 30, 2024AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSApril 3, 2024Summary of the live webcast held on March 4, 2024, providing an update on AB Science developmentMarch 7, 2024Two financial analysis firms initiate coverage of AB ScienceMarch 6, 2024
A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientsMay 7, 2024
The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceMay 2, 2024
AB Science announces a slight delay in the publication of its 2023 annual financial reportApril 30, 2024
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSApril 3, 2024
Summary of the live webcast held on March 4, 2024, providing an update on AB Science developmentMarch 7, 2024